MYL(SH:600993)2025-04-02 12:35Financial Performance - In 2024, the company's operating revenue reached ¥3,728,023,668.64, an increase of 18.85% compared to ¥3,136,746,407.53 in 2023[22]. - The net profit attributable to shareholders of the listed company was ¥528,093,859.48, reflecting a year-on-year growth of 19.14% from ¥443,250,935.32 in 2023[22]. - The basic earnings per share increased to ¥1.23, up 19.42% from ¥1.03 in 2023[23]. - The net profit after deducting non-recurring gains and losses was ¥510,857,286.05, a significant increase of 44.98% compared to ¥352,367,707.07 in 2023[22]. - The company reported a total of ¥17,236,573.43 in non-recurring gains for 2024, compared to ¥90,883,228.25 in 2023[28]. - The cash and cash equivalents at the end of 2024 were ¥4,065,961,926.61, an increase of 8.77% from ¥3,737,968,219.51 at the end of 2023[22]. - The company achieved a revenue of 3.728 billion yuan in 2024, representing a year-on-year growth of 18.85%[66]. - The net profit attributable to the parent company was 528 million yuan, an increase of 19.14% year-on-year, while the net profit excluding non-recurring gains and losses was 511 million yuan, reflecting a significant growth of 44.98%[68]. Dividend Distribution - The company plans to distribute a cash dividend of 6.20 CNY per 10 shares, totaling 267,253,412.42 CNY, which accounts for 50.61% of the audited net profit attributable to shareholders[7]. - The cash dividend amount distributed in 2023 was 172,421,556.40 RMB, with a per-share distribution of 0.4 RMB (including tax) based on a total share capital of 431,053,891 shares[159]. - The cumulative cash dividend amount over the last three accounting years is 590,543,830.67 RMB[163]. Audit and Compliance - The company has received a standard unqualified audit report from Zhongshen Zhonghuan Accounting Firm[6]. - The board of directors has ensured the authenticity, accuracy, and completeness of the annual report[4]. - The company has not violated decision-making procedures for external guarantees[9]. - The company has not faced any penalties from securities regulatory agencies in the past three years[140]. - The internal control audit report for the fiscal year 2024 received a standard unqualified opinion[168]. Risk Management - The company has detailed potential risks in the report, which can be found in the "Management Discussion and Analysis" section[9]. - The company is actively managing risks related to industry policies, R&D, quality control, raw material price fluctuations, and environmental regulations[124][125]. - The company has established a comprehensive quality management system to ensure product safety and compliance with regulatory standards[125]. - The company has a robust risk management framework in place to enhance its overall risk resilience[123]. Research and Development - The company completed 60 independent research and development projects in the health sector, laying a solid foundation for future market expansion[37]. - The company focuses on drug research and development in the core areas of anorectal and lower gastrointestinal tract, with a pipeline that includes both chemical and traditional Chinese medicine products[104]. - Major R&D projects include MYL ointment for hemorrhoid symptoms, MC-001 for chronic functional constipation, and various eye drops, with significant investments in each project[105][111]. - The R&D investment for the reporting period was 2.88% of operating income, with a total investment of approximately 2,000 million RMB across various projects[112]. Market and Industry Trends - The national retail pharmacy market in 2024 reached a cumulative sales scale of CNY 528.2 billion, a year-on-year decline of 2.2%, with the pharmaceutical market accounting for 82.8% of the total, showing a growth of 0.3%[43]. - The company has transitioned from a pharmaceutical manufacturer to a health solution provider, focusing on the health industry and forming an industrial layout of pharmaceutical manufacturing, medical services, and pharmaceutical commerce[53]. - The company’s hemorrhoid ointment was recognized as a single champion product in the fourth batch of manufacturing single champion enterprises by the Ministry of Industry and Information Technology in 2019, and it successfully passed the re-evaluation in November 2022[53]. Corporate Governance - The company held 6 board meetings and 5 supervisory meetings during the reporting period, ensuring effective governance and decision-making processes[128]. - The total pre-tax remuneration for the board members and senior management during the reporting period amounted to CNY 1,575.59 million[134]. - The company has a total of 15 board members and supervisors, with a diverse background in various industries, enhancing its governance structure[133]. - The company has a structured approach to managing changes in its leadership team, ensuring continuity in governance[139]. Environmental and Social Responsibility - The company invested approximately 2.11 million in environmental protection during the reporting period[171]. - The company has been classified as a key pollutant discharge unit by the Wuhan Ecological Environment Bureau[172]. - The company has implemented a self-monitoring plan for environmental pollutants, with specific monitoring frequencies for various pollutants[180]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[181]. Financial Management - The company has invested a total of 824.28 million RMB in bank wealth management products and 1.11995 billion RMB in securities firm wealth management products[195]. - The company is actively managing its financial products with varying yields and expected returns, indicating a strategic approach to asset management[199]. - The overall financial strategy appears to be aimed at maximizing returns while managing risk through diversified investments[200].